Most side effects were gastrointestinal and mild-to-moderate
Why Dose Timing Matters for Month-One Expectations Most patients begin semaglutide at a low starting dose set by their prescriber, to permit assessment of gastrointestinal tolerance
doi: 10.1016/j.chest.2025.03.030, 18
The analysis included 10,997 adults with CM initiating a GLP-1 RA (liraglutide, semaglutide, dulaglutide, exenatide, lixisenatide, or albiglutide) within 12 months of diagnosis, as well as matched adults initiating topiramate.The researchers found that compared with topiramate, GLP-1 RA initiators had a lower risk for emergency department visits (risk ratio [RR], 0.90), hospitalizations (RR, 0.86), nerve blocks (RR, 0.87), and triptan use (RR, 0.87)